Alterations in adipocyte glucose transporter GLUT4 and circulating adiponectin and visfatin in rat adjuvant induced arthritis

Jana Jurčovičová1,2, Andrea Štofková2, Martina Škurlová2, Miroslava Baculíková1, Štefan Zórad1 and Mária Stančíková3

1 Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovakia
2 Department of Normal, Pathological and Clinical Physiology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
3 Institute for Rheumatic Diseases, Piešťany, Slovakia

Abstract. Rheumatoid arthritis in humans brings about impaired insulin sensitivity and glucose tolerance. Since adipose tissue plays a role in glucose homeostasis, we evaluated the size of adipocytes, the amount of glucose transporter type 4 (GLUT4) in adipocyte plasma membranes, and circulating insulin, glucose, and adipokines affecting glucose metabolism, resistin, adiponectin and visfatin during experimental adjuvant arthritis (AA) in male Lewis rats. AA was induced by a single injection of complete Freund’s adjuvants. Adipocyte diameter was assessed microscopically, GLUT4 was measured by Western blotting. Plasma insulin, adiponectin, visfatin were quantitated by RIA, and resistin by ELISA. Arthritic rats showed cachexia, reduced adipocyte size, and downregulated membrane GLUT4 (4065 ± 962 vs. 9911 ± 680 arb. units of optic density, p < 0.01), reduced plasma adiponectin (1.956 ± 0.10 vs. 3.16 ± 0.22 µg/ml, p < 0.001), and enhanced visfatin (1.84 ± 1.05 vs. 1.24 ± 0.1 ng/ml, p < 0.01). Plasma glucose and insulin were unaltered, as were the resistin levels. Conclusion: AA induced cachexia results in reduction of adipocyte size, and paradoxically also in downregulation of GLUT4 in adipocyte membranes. This is supposed to be functionally related to the reduced adiponectin levels. The upregulated visfatin in rat arthritis is a novel finding, and it confirms its role in autoimmunity across the species.

Key words: Adjuvant arthritis — Adipocytes — GLUT4 — Visfatin — Adiponectin

Introduction

Numerous clinical studies evidenced metabolic consequences of rheumatoid arthritis (RA), often leading to insulin resistance and metabolic syndrome in these patients (Dessein et al. 2006; Sidiropoulos et al. 2008). It has been known that the systemic inflammatory process characteristic of RA brings about changes in a whole array of adipokines that may further affect the severity of the disease.

Resistin has been first found to induce insulin resistance and glucose intolerance in obesity (Steppan et al. 2001; Guzik et al. 2006). More recently a local proinflammatory role has been ascribed to resistin, since it stimulated interleukin-6 and tumor necrosis factor-a in human leukocytes, its enhanced local joint production in patients with RA was observed and its intra-articular administration to mice induced inflammation (Bokarewa et al. 2005). Moreover, in severe RA higher resistin levels occurred in the circulation (Senolt et al. 2007).

Adiponectin is known to enhance insulin sensitivity in the tissue. It promotes insulin regulated glucose transport by its direct action on the GLUT4 transporter expression and translocation into plasma membrane to ameliorate insulin resistance (Fu et al. 2005). Adiponectin has been found in the synovial adipocytes and fibroblasts of RA patients. In the joint it stimulated interleukin-6 production and matrix degrading enzymes suggesting its local proinflammatory activity (Ehling et al. 2006). Adiponectin was also enhanced
in the circulation and synovial fluid of RA patients (Otero et al. 2006; Senolt et al. 2006).

Visfatin (nicotinamide phosphoribosyltransferase – NAMPT), was originally described as pre-B-cell colony-enhancing factor (Samal et al. 1994), and later as insulin-mimetic adipokine secreted from visceral fat (Fukuhara et al. 2005). Subsequently visfatin/NAMPT was shown to act as an extracellular NAD biosynthetic enzyme critical for glucose-stimulated insulin secretion in pancreatic β-cells (Revollo et al. 2007). Recent study revealed that visfatin can improve insulin sensitivity by enhancing insulin receptor substrate-1 phosphorylation, as well as by up-regulation of peroxisome proliferator-activated receptor-γ in fat tissue (Sun et al. 2009). Visfatin has been qualified as a proinflammatory agent with matrix degrading activity in the synovial tissue. At the same time its levels in circulation and in synovial fluid have been enhanced in patients with RA (Otero et al. 2006; Brentano et al. 2007).

Rat adjuvant arthritis (AA) represents a widely used experimental model for RA. A single subcutaneous injection of a suspension of heat killed Mycobacterium butyricum in mineral oil develops polyarthritis. The disease exhibits a dynamic progression with an initial, preclinical phase followed within about 10 days by acute clinical phase which reaches peak intensity around day 20. It is characterized by a number of changes occurring in human RA. In Lewis arthritic rats from day 12 onwards the loss of appetite is accompanied by reduction in plasma levels of leptin, adiponectin, and also by downregulation of the negative inosines involved in insulin metabolism and arthritis, resistin phosphorylation, as well as by up-regulation of peroxisome proliferator-activated receptor-γ in fat tissue (Sun et al. 2009). Visfatin has been qualified as a proinflammatory agent with matrix degrading activity in the synovial tissue. At the same time its levels in circulation and in synovial fluid have been enhanced in patients with RA (Otero et al. 2006; Brentano et al. 2007).

Materials and Methods

Animals

Male Lewis 8-weeks old rats (Charles River, Germany) were housed four per cage in an animal room in the Department of Normal, Pathological and Clinical Physiology, Third Faculty of Medicine, Charles University, Prague. They were treated according to the national law of the Czech Republic on the use of laboratory animals, No. 167/1993. AA was induced to rats by a single subcutaneous injection of 100 μl of complete Freund’s adjuvant (CFA) into the base tail. Rats were decapitated on day 18 after CFA injection along with intact controls (8 rats per group). Trunk blood was collected into EDTA, centrifuged and plasma was stored at –30°C until assayed. Epididymal fat was taken to measure adipocyte size and GLUT4 in adipocyte plasma membranes. We analyzed epididymal fat only, because the amount of any other fat is extremely limited in arthritic animals, and is not sufficient for analyses.

Diameter of adipocytes and GLUT4 measurement

One part of epididymal fat was used for adipocyte size determination. Adipocytes were isolated by collagenase digestion (Pinterova et al. 2001) and the fat cell size was assessed microscopically. The cells were photographed using a camera (Canon Digital Power Shot S40) attached to the microscope and the cell diameter was calculated. Resulting diameter is an average value of at least 100 cells from each adipocyte suspension. The rest of the epididymal fat was homogenized, and plasma membranes were isolated as detailed previously (Baculikova et al. 2008). For GLUT4 Western blot, 20 μg solubilized fat tissue membranes were separated by electrophoresis on 12% TRIS-glycine polyacrylamide gel and then electrotransferred to Hybond C Extra membrane (Amersham Bioscience, Buckinghamshire, UK). After blocking for 1 h in TBS with 5% milk, the membrane was incubated overnight at 4°C with primary rabbit anti-GLUT4 antibody (Abcam, Cambridge, UK) diluted 1 : 2500 in 10 mmol/l Tris – 150 mmol/l NaCl buffer, pH 7.4 (TBS) with 0.2% Igepal (Sigma, St. Louis, USA). The membrane was washed in TBS-Igepal buffer and then incubated with horseradish peroxidase-conjugated secondary antibody (goat anti-rabbit IgG, 1 : 15 000, Sigma, St. Louis, USA) for 1 h at room temperature. After washing the membrane was exposed to chemiluminescence reagent (Amersham Bioscience, Buckinghamshire, UK) and exposed to X-ray film. The chemiluminescence signal was acquired by densitometric scanning.

Analyses

Albumin was determined by spectrophotometric method using SYS 1 kit (BM/Hitachi, Boehringer Mannheim, Germany) on Hitachi 911 automatic biochemical analyzer (Boehringer Mannheim, Germany). Insulin, adiponectin and visfatin concentrations were determined by the respective RIAs (Linco Research, USA), resistin by ELISA (BioVendor, Czech Republic) or glucose using auto-analyzer Hitachi 911 (Hitachi, Japan). The data were analyzed by unpaired Student’s t-test. Statistical significance is considered at p < 0.05.
Results

The hind paw volumes were significantly enlarged in AA rats that correlated with overall cachexia typical for the developed phase of AA. As expected, the epididymal fat stores were significantly smaller in arthritic rats (422 ± 70 mg vs. 1184 ± 105 mg in controls, \( p < 0.001 \)), and similarly body mass was reduced (201 ± 25.9 g vs. 325 ± 2.9 g in controls, \( p < 0.001 \)). AA markedly inhibited the production of albumin levels in rat. It occurred as a result of enhanced acute phase proteins synthesis by the liver secondary to the activation of hepatic cells by inflammatory cytokines (Figure 1).

The body and fat mass loss resulted in a reduction of adipocyte diameter. Furthermore the fat cells clearly showed downregulation of GLUT4 translocation into the cell membranes. Inflammation did not affect either glucose, or insulin plasma levels at unrestricted food intake (Figure 2). In the Figure 3 are depicted values for circulating adipokines. Plasma resistin levels, in spite of its described role in autoimmune inflammation remained unchanged under our conditions. However, circulating adiponectin involved in GLUT4 regulation was reduced along with the reduction of fat mass. On the other hand, the levels of circulating visfatin were enhanced in arthritic rats that inversely correlated to the reduced fat mass.

Discussion

Here we described reduced adipocyte diameter, and a clearcut downregulation of GLUT4 in the adipocyte plasma membranes in the fully developed phase of AA characterized by joint swelling, body and fat mass loss, and reduction of albumin production. At the same time we found unaffected basal glucose and insulin levels, unchanged circulating resistin, but reduced adiponectin and enhanced visfatin levels.

Physiological reduction of fat mass is usually associated with an increase in insulin sensitivity and upregulation of GLUT4 in adipocytes. For example, 40% caloric restriction reversed insulin resistance in pinealectomized rats by enhancing GLUT4 content in adipocytes and its translocation to the plasma membranes (Zanquetta et al. 2003). Similarly in fatty rats caloric restriction improved glucose utilization by upregulation of adipocyte GLUT4 expression (Park et al. 2005). Under the conditions of clinically manifested AA the loss of appetite occurs, that is manifested by reduced food consumption by about 40%, and consequently by body and fat mass loss (Stofkova et al. 2009). The inflammatory reduction of GLUT4 in adipocyte plasma membranes, that we observed, is a specific phenomenon that can not be attributed to lowered caloric intake, but mirrors the adipokine imbalance during the disease. Since we confirmed this

![Figure 1](image1.png)

**Figure 1.** Clinical signs of adjuvant arthritis represented by paw edema (A), loss of body weight (B), and epididymal fat (C). The enhanced production of acute phase proteins is manifested by decreased albumin production (D). Each column represents mean of 7–8 animals fed *ad libitum* ± S.E.M. ** \( p < 0.01 \); *** \( p < 0.001 \); C, intact control rats; AA, arthritic rats on day 18 of the disease.
finding also in the Long Evans arthritic rats (unpublished), we assume that it is a general feature accompanying autoimmune experimental arthritis.

Our result on the reduction of circulating adiponectin levels during AA confirm the recent finding of Haruna et al. (2007), Martin et al. (2008), and our own observation (Stofkova et al. 2009) in the clinical phase of AA, and suggests that this may be involved in the downregulation of GLUT4 in adipocytes. Any interpretation of reduced adiponectin plasma levels related to the severity of the disease can not be drawn, because the decisive role plays its intraarticular production. Regarding the unaltered resistin levels in our experiment, we assume that in spite of its defined local proinflammatory activity, circulating resistin is not an important factor in the development of AA. In this study we described for the first time enhanced visfatin/NAMPT levels in arthritic rats. Visfatin/NAMPT has been shown to be upregulated in the activated immune cells (Rongvaux et al. 2002), and recently Busso et al. (2008) showed its enhanced levels in the circulation and in the inflamed paws in collagen-induced arthritis (CIA) in mice as well. These authors clearly demonstrated its role in the pathology of the disease.

Figure 2. Diameter of adipocytes (A), and the amount of GLUT4 (B), in adipocyte plasma membranes in normal and arthritic rats. The bands stand for representative Western blot of GLUT4 in 5 healthy and 5 arthritic animals. In the lower part are depicted plasma insulin (C) and glucose (D) levels in rats. Each column represents mean of 7–8 animals fed ad libitum ± S.E.M. * p < 0.05; *** p < 0.001; C, intact control rats; AA, arthritic rats on day 18 of the disease; OD, optic density.

Figure 3. Plasma adiponectin (A), visfatin (B), and resistin (C) in normal and arthritic rats. Each column represents mean of 7–8 animals fed ad libitum ± S.E.M. *** p < 0.001; C, intact control rats; AA, arthritic rats on day 18 of the disease.
since its pharmacological blockade improved the clinical features of CIA. Whether enhanced visfatin levels acts also to compensate insulin insensitivity due to lack of GLUT4, and maintains unaltered basal insulin and glucose during autoimmunity, warrants further study.

In conclusion, AA-induced cachexia results in reduction of adipocyte size, and paradoxically also in downregulation of GLUT4 in adipocytes. This is supposed to be related to the reduced adiponectin levels. The enhanced visfatin levels in rat AA is a novel finding demonstrating that this occurs across the species, and rat AA provides a relevant model for further study of its mechanisms.

Acknowledgements. This work was supported by GACR 305/06/0427, VZ 00216 208 16 and APVV 21-055205 grants.

References


Received: April 13, 2009
Final version accepted: October 19, 2009